{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-002343","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2023-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.049941+00:00","generated_at":"2026-06-20T15:50:21.055889+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Oramed Phase 3 oral insulin trial fails; discontinues T2D program","bullets":["Phase 3 ORA-D-013-1 of ORMD-0801 missed primary endpoint: mean A1C change at 26 weeks.","Secondary endpoint (fasting plasma glucose) also missed; no serious drug-related adverse events.","Company will discontinue all oral insulin clinical activities for type 2 diabetes."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-002343","json":"https://secwatch.observer/filing/0001213900-23-002343.json","markdown":"https://secwatch.observer/filing/0001213900-23-002343.md","text":"https://secwatch.observer/filing/0001213900-23-002343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023002343/0001213900-23-002343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390023002343/ea171576-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T15:50:21.055889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}